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The purpose of this study is to review recent scientific advances relating to the natural history, cause,
treatment and serum and imaging biomarkers of inclusion body myositis (IBM).
Recent findings
Several theories regarding the aetiopathogenesis of IBM are being explored and new therapeutic
approaches are being investigated. New diagnostic criteria have been proposed, reflecting the knowledge
that the diagnostic pathological findings may be absent in patients with clinically typical IBM. The role of MRI
in IBM is expanding and knowledge about pathological biomarkers is increasing. The recent description of
autoantibodies to cytosolic 50 nucleotidase 1A in patients with IBM is a potentially important advance that
may aid early diagnosis and provides new evidence regarding the role of autoimmunity in IBM.
Summary
IBM remains an enigmatic and often misdiagnosed disease. The pathogenesis of the disease is still not fully
understood. To date, pharmacological treatment trials have failed to show clear efficacy. Future research
should continue to focus on improving understanding of the pathophysiological mechanisms of the disease
and on the identification of reliable and sensitive outcome measures for clinical trials. IBM is a rare disease
and international multicentre collaboration for trials is important to translate research advances into
improved patient outcomes.
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Sporadic inclusion body myositis (IBM) is the com-
monest acquired myopathy in patients aged over
50 years [1]. It is classified along with polymyositis,
dermatomyositis and immune-mediated necrotiz-
ing myopathies as an idiopathic inflammatory
myopathy. However, IBM is distinguished from
these other disorders by asymmetric finger flexor
and knee extensor weakness [2] and resistance to
immunosuppressive therapy [3]. Several patho-
logical findings on muscle biopsy are considered
as synonymous with the diagnosis of IBM: an endo-
mysial inflammatory infiltrate, invasion of nonne-
crotic muscle fibres by inflammatory cells (partial
invasion), rimmed vacuoles, amyloid and 15–18nm
tubulofilaments on electron microscopy. Combi-
nations of these features have formed the basis of
successive diagnostic criteria for IBM [4–7]. How-
ever, these histological findings may not all be
present in patients with a clinically typical IBM
[3,8]. This is reflected by the inclusion of a clinically
defined group in the new 2011 European Neuro-
muscular Centre (ENMC) diagnostic criteria [9],
which build on the MRC Centre criteria [10,11].
New developments include the description ofilliams & Wilkins. Unau
Health | Lippincott Williams & Wilkautoantibodies to cytosolic 5 nucleotidase 1A
(cN1A) in patients with IBM [12,13
&&
,14
&&
]. Two
recently published studies [13
&&
,14
&&
] assess their
diagnostic use in IBM. This review focuses on our
current knowledge of IBM with particular emphasis
on developments in the last 24 months in disease,
serum and imaging biomarkers and on on-going and
future therapeutic trials.
NATURAL HISTORY STUDIES
Recent studies [3,15,16
&
,17] investigating the
natural history of IBM have confirmed the typicalthorized reproduction of this article is prohibited.
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CKEY POINTS
 New diagnostic criteria have been proposed by the
European Neuromuscular Centre (ENMC).
 Antibodies against the cytosolic 50-nucleotidase 1A are
a new serum biomarker of IBM.
 New therapeutic approaches are being tested in IBM.
 Precise aetiopathogenesis of IBM remains uncertain.
 No new pathological biomarkers can currently be
recommended for diagnostic purposes, though
immunohistochemical staining for some such as p62
and TDP-43 show promise.
Myositis and myopathiesearly disease phenotype and highlighted that IBM is
often initially misdiagnosed, polymyositis being the
most common incorrect initial diagnosis. They have
also shown that survival in patients with IBM seems
to be similar to the general population, but late-
stage disease can cause very significant morbidity,
including disability and reduced quality of life.
Death in IBM is related to malnutrition, cachexia,
aspiration, respiratory infection and respiratory fail-
ure, as a consequence of dysphagia, severe global
weakness and weakness of the respiratory muscles
[3,17]. In aDutch cohort [17], euthanasia or continu-
ous deep sedation was used by 13% of patients with
IBM, in comparisonwith 20%of patients with amyo-
trophic lateral sclerosis [12]. These data highlight the
morbidity experienced by IBM patients and the
importance of supportive and palliative care in IBM.
Regarding prognostic factors, Benveniste et al.
[3] found that male sex [hazard ratio 2.4, 95%
confidence interval (95% CI) 1.5–3.9], older age
(>60 years) (hazard ratio 2.0, 95% CI 1.3–3.1) and
immunosuppressive treatment (hazard ratio2.1, 95%
CI 1.3–3.3) were predictive of progression of disease
towards handicap forwalking.However, once awalk-
ing aid was needed, progression towards the use of a
wheelchair was not associated with these variables.
Cortese et al. [16
&
] also found that older age
(>55years) at disease onsetwaspredictiveof a shorter
time to requirement of a walking stick (hazard ratio
4.1, 95% CI 1.7–9.8), but not sex or treatment.
Prospective data in IBM are scarce and limited to
small numbers of patients [15,16
&
,17–20]. Mean
decline inmuscle strength bymanualmuscle testing
was 3.51.6%per year in the study by Cox et al. [17]
and 5.25.9% over 1 year in the study by Cortese
et al. [16
&
]. Quantitativemuscle testing of quadriceps
extensors and the IBM functional rating scale may
be sensitive tools to monitor disease progression
[15,16
&
,21,22].opyright © Lippincott Williams & Wilkins. Unautho
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Muscle biopsies from patients with IBM typically
show several different pathological features, broadly
described as inflammatory or degenerative. Haema-
toxylin and eosin (H&E) staining reveals fibre
necrosis and regeneration, rounded atrophic fibres,
split fibres and eosinophilic inclusions (Fig. 1). Evi-
dence of neurogenic atrophy may sometimes be
seen. Using more specialist techniques, a number
of other pathological features have been described
such as protein accumulations, increased major his-
tocompatibility complex class I (MHC Class I)
expression and mitochondrial changes [e.g. the
presence of cytochrome c oxidase (COX) negative
fibres]. Tubulofilaments visualized within fibres
using electron microscopy were the first patho-
logical abnormality associated with IBM [23]. Sub-
sequently, rimmed vacuoles and amyloid were
described [24,25]. Although all the diagnostic
pathological features associated with IBM have all
been documented in other myopathies, in combi-
nation they are still considered to be highly specific
for IBM. However, clinical experience and studies
[3,8] have shown that they lack sensitivity. Despite
long-standing awareness of the presence of these
pathological features in IBM, it remains unclear
how they relate to disease pathogenesis.
More recently, using immunohistochemical
techniques, many different proteins have been
found accumulated in IBM, leading to its descrip-
tion as a ‘promiscuous proteinopathy’ [26]. The
proteins described are associated with different
cellular processes such as inflammation, autophagy
and endoplasmic reticulum stress. Many proteins
reported in IBM were originally described in neuro-
degeneration, leading some authors to identify sim-
ilarities between the pathogenesis of IBM and
neurodegenerative conditions such as Alzheimer’s
disease. However, the validity of some of these
findings is uncertain and has been questioned by
others [27]. Currently, none of the protein aggre-
gates described in the literature can be clearly
recommended for diagnostic use in IBM, though
present evidence appears to favour p62 and TAR
DNA-binding protein 43 (TDP-43) as potential
biomarkers. The absence of partial invasion and
COX-negative fibres appears to be good evidence
against a diagnosis of IBM [28]. A comprehensive
review of pathological biomarkers has been recently
published [29].AETIOPATHOGENESIS
The aetiopathogenesis of IBM remains uncertain.
The varied pathological findings observed have
driven a number of theories, including viralrized reproduction of this article is prohibited.
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(a) (b)
(c) (d)
(e) (f)
FIGURE 1. Pathological features observed in IBM. Muscle biopsy from a patient with IBM showing fibres containing rimmed
vacuoles (a), amyloid in a tissue section stained using Congo red and visualised under fluorescent light (b) and tubulofilaments
observed using electron microscopy (c). Immunohistochemically stained tissue sections reveal increased sarcolemmal and
sarcoplasmic major histocompatibility complex class I (MHC Class I) expression (d) and fibres containing sarcoplasmic p62
immunoreactive aggregates (e) and TAR DNA-binding protein 43 (TDP-43) immunoreactive aggregates with loss of normal
myonuclear TDP-43 staining (f). Scale bar in A represents 50 mm in (a), (b), (d), (f); 25 mm in (e); and 0.7 mm in (c).
Update in inclusion body myositis Machado et al.infection, accumulation of toxic proteins, auto-
immune attack, myonuclear degeneration, endo-
plasmic reticulum stress and impairment of
autophagy and proteasomal proteolysis. In addition
to inflammatory changes, much of the recent
work has focused on myonuclear degeneration
and autophagy.
Myonuclear abnormalities are not uncommon
in IBM. The presence of nuclear and lysosomal
proteins in rimmed vacuoles led to the hypothesis
that they are derived from degenerating myonuclei
[30–32]. Further evidence of myonuclear involve-
ment in the pathogenesis of IBM is suggested by the
loss of myonuclear TDP-43 [33,34] and the presence
of myonuclear protein aggregates. SarcoplasmicCopyright © Lippincott Williams & Wilkins. Unau
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of the most abundant protein aggregates in IBM,
found in up to 23% of fibres, suggesting that TDP-43
redistribution may play a significant role in the
pathogenesis [34]. There is some evidence that
TDP-43 loss from the myonuclei leads to abnormal-
ities in themorphology of nuclei and apoptosis [35].
However, sarcoplasmic TDP-43 aggregates are not
specific to IBM [33,36,37] and other publications
have not reported such abundant changes [38].
Autophagy is responsible for the degradation of
long-lived cytosolic proteins and organelles.
Initially, it was thought to be an indiscriminate
process; however, there is increasing evidence of
its selectivity [39]. Impairment of autophagy leadsthorized reproduction of this article is prohibited.
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CMyositis and myopathiesto the accumulation of p62 [40,41]. p62 and a
number of other autophagy-associated proteins,
including LC3 and neighbour of BRCA 1 gene 1
(NBR1), have been found to be increased in IBM
[38,42,43]. Whether this reflects impairment of
autophagic degradation or increased autophagic
turnover is unknown. In addition to degrading
and recycling cellular organelles such as mitochon-
dria, autophagy may also affect MHC Class I turn-
over. Therefore, abnormalities in this pathway may
explain several of the varied pathological features
observed in IBM.DIAGNOSTIC CRITERIA
The first diagnostic criteria for IBM were proposed
by Calabrese et al. [44]. These required the presence
ofmicrotubular filaments in inclusions and rimmed
vacuoles for a diagnosis of definite IBM and pro-
bable IBM respectively, reflecting the belief that
these pathological findings were sensitive and
specific for IBM. Further criteria were proposed by
Lotz et al. [5]. They found that rimmed vacuoles,
atrophic fibres, endomysial autoaggressive inflam-
matory exudate and tubulofilaments were essen-
tial pathological features for a diagnosis of IBM.
However, these criteria were based solely on theopyright © Lippincott Williams & Wilkins. Unautho
Table 1. 1995 Griggs diagnostic criteria
Criteria type Features
Clinical features 1. Duration of illness >6 months
2. Age of onset >30 years old
3. Muscle weakness affecting proximal and dista
the following features:
a. Finger flexion weakness
b. Wrist flexion weakness > wrist extension w
c. Quadriceps muscle weakness (grade 4 M
Laboratory features 4. Serum creatine kinase <12 times normal
5. Muscle biopsy
a. Inflammatory myopathy characterixed by m
b. Vacuolated muscle fibres
c. Either
i. Intracellular amyloid or
ii. 15–18nm tubulofilaments
6. Electromyography must be consistent with fea
Definite IBM Patients must exhibit all muscle biopsy features, i
vacuolated muscle fibres and intracellular (with
Possible IBMa If the muscle biopsy shows only inflammation (inv
other pathological features of IBM, then a diag
characteristic clinical (1–3) and laboratory (4,
Adapted from [4].
aIn the text of the original article by Griggs et al. [4], possible IBM can be diagnose
15–18nm tubulofilaments; therefore, an inflammatory infiltrate characterised by mo
would be a necessary feature.
766 www.co-rheumatology.comanalysis of patients with rimmed vacuoles on
muscle biopsy.
The seminal Griggs criteria were published in
1995 (Table 1) [4]. These are similar to the two
previous criteria and therefore pathologically
focused. Using the Griggs criteria, a diagnosis of
definite IBM could be made on the basis of the
pathological findings alone. In the absenceof tubulo-
filaments and amyloid, a diagnosis of possible IBM
could be made but required additional clinical and
laboratory criteria to be satisfied. Amendments to the
criteria, including the assessment of mitochondrial
changes and MHC Class I upregulation, have been
suggested but not widely adopted [45]. The first
ENMC diagnostic criteria were published in 1997
[7]. A significant change was the ability to make
the diagnosis in the absence of rimmed vacuoles
and tubulofilaments (Table 2) [46].
It is now recognized that, although the patho-
logical findings are highly specific when present in
combination, they lack sensitivity. However, the
combination of selective weakness of finger flexion
and knee extension is believed to be typical of IBM
and not present in other myopathies. To address
this, more recent criteria [10,11], including the 2011
ENMC diagnostic criteria (Table 3) [9,47], include a
category of clinically defined IBM.rized reproduction of this article is prohibited.
l muscles of arms and legs and patient must exhibit at least one of
eakness
RC)
ononuclear cell invasion of nonnecrotic muscle fibres
tures of an inflammatory myopathy
ncluding invasion of nonnecrotic fibres by mononuclear cells,
in muscle fibres) amyloid deposits or 15–18nm tubulofilaments
asion of nonnecrotic muscle fibres by mononuclear cells) without
nosis of possible IBM can be given if the patient exhibits the
6) features
d if the muscle biopsy fails to show intracellular amyloid deposits and
nonuclear cell invasion of nonnecrotic fibres and vacuolated muscle fibres
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Table 2. 2007 European Neuromuscular Centre diagnostic criteriaa
Criteria type Features
Clinical 1. Presence of muscle weakness
2. Weakness of forearm muscles, particularly finger flexors, or wrist flexors more than wrist extensors
3. Slowly progressive course
4. Sporadic disease
Histopathology 5. Mononuclear inflammatory infiltrates with invasion of nonnecrotic muscle fibres
6. Rimmed vacuoles
7. Ultrastructure: tubulofilaments of 16–21nm
Definite IBM 1,2,3,4,5,6 or 1,3,4,5,6,7
Probable IBM 1,2,3,4,5 or 1,3,4,5,6
aAdapted from [46].
Update in inclusion body myositis Machado et al.AUTOANTIBODIES TO CYTOSOLIC
50-NUCLEOTIDASE 1A
In 2011, Salajegheh et al. [12] reported an autoanti-
body against a 43-kDa muscle antigen highly
specific for IBM. This autoantibody was recently
identified by the same group as targeting the
cN1A [13
&&
]. The authors have also shown that in
IBMmuscle sections stainedwith a commercial anti-
cN1A antibody, immunoreactivity was predomi-
nantly located to perinuclear regions and rimmed
vacuoles [13
&&
].Copyright © Lippincott Williams & Wilkins. Unau
Table 3. 2011 European Neuromuscular Centre diagnostic
Clinical features Classification
Duration of weakness >12 months Clinicopathol
Creatine kinase 15 ULN
Age at onset >45 years
Finger flexion weakness > shoulder abduction weakness
AND/OR
Knee extension weakness  hip flexor weakness
Duration of weakness >12 months Clinically def
Creatine kinase 15 ULN
Age at onset >45 years
Finger flexion weakness > shoulder abduction weakness
AND
Knee extension weakness  hip flexor weakness
Duration of weakness >12 months Probable IBM
Creatine kinase 15 ULN
Age at onset >45 years
Finger flexion weakness > shoulder abduction weakness
OR
Knee extension weakness  hip flexor weakness
aDemonstration of amyloid or other protein accumulation by established methods (e.
SMI-31, TDP-43). Current evidence favours p62 in terms of sensitivity and specificity
histocompatibility complex class I; ULN, Upper limit of normal.
1040-8711  2013 Wolters Kluwer Health | Lippincott Williams & WilkSimultaneously, an independent European
group reported an autoantibody against a 44-kDa
muscle antigen. This antibody was named anti-
Mup44 and its target was identified as also being
the cN1A [14
&&
]. The antibodies identified by these
two groups are therefore targeting the same antigen
and the very small difference in molecular weights
(43 versus 44 kDa) is probably related to methodo-
logical variation between laboratories [13
&&
,14
&&
].
The diagnostic performance of anti-cN1A reac-
tivity was very good. Results were consistent acrossthorized reproduction of this article is prohibited.
criteria [9,47]
Pathological features
ogically defined IBM All of the following:
Endomysial inflammatory infiltrate
Rimmed vacuoles
Protein accumulationa or 15–18nm filaments
ined IBM One or more, but not all, of:
Endomysial inflammatory infiltrate
Upregulation of MHC Class I
Rimmed vacuoles
Protein accumulationa or 15–18nm filaments
One or more, but not all, of:
Endomysial inflammatory infiltrate
Upregulation of MHC Class I
Rimmed vacuoles
Protein accumulationa or 15–18nm filaments
g. for amyloid Congo red, crystal violet, thioflavin T/S, for other proteins p62,
, but the literature is limited and further work is required. MHC Class I, Major
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CTable 4. Sensitivity and specificity (high and low antibody titres) of anti-cN1A antibodies for the diagnosis of
IBM in the group of patients with neuromuscular diseases and in the subgroup of patients with inflammatory
myopathiesa,b
Study
High titrec Low titrec
N-total (% IBM) Sensitivity Specificity Sensitivity Specificity
Patients with neuromuscular diseases (i.e. excluding healthy controls)
Larman et al. [13&&] 165 (28%) 34% 98% 70% 92%
Pluk et al. [14&&] 234 (40%) 33% 96% 60% 89%
Subgroup of patients with inflammatory myopathies (IBM, PM, DM and IMNM)
Larman et al. [13&&] 123 (38%) 34% 97% 70% 89%
Pluk et al. [14&&] 140 (67%) 33% 96% 60% 83%
cN1A, cytosolic 50 -nucleotidase 1A; DM, dermatomyositis; IBM, inclusion body myositis; IMNM, immune-mediated necrotizing myopathy; N-total (% IBM), total
number of patients (percentage of IBM patients); PM, polymyositis.
aStudy population in Larman et al. [13
&&
]: 47 patients with IBM, 26 with PM, 36 with DM, 14 with IMNM, 13 with myasthenia gravis, 4 with myotonic
dystrophy, 4 with limb-girdle muscular dystrophy, 1 with myofibrillar myopathy, 1 with distal myopathy with rimmed vacuoles, 19 with other muscular diseases
and 35 healthy controls.
bStudy population in Pluk et al. [14
&&
]: 94 patients with IBM, 24 with DM, 22 with PM, 94 with other neuromuscular disorders and 32 healthy controls.
cHigh and low anti-cN1A titres (reactivities) were defined as >10 intensity units (IU) (scaled threshold based on the dot blot densitometry mean plus 3 standard
deviations for the 35 tested healthy individuals) and >2.5 IU, respectively, in the study by Larman et al. [13
&&
], and as >5 and >1% precipitation of the input
cN1A protein, respectively, in the study by Pluk et al. [14
&&
].
Myositis and myopathiesthe two studies [13
&&
,14
&&
], with sensitivities of
60–70% and specificities of 83–92% for low anti-
body titres, and sensitivities of 33–34% and speci-
ficities of 96–98% for high antibody titres (Table 4).
This new antibody has therefore significant poten-
tial utility in clinical practice and re-launches the
debate about the role of autoimmunity in IBM
pathogenesis.IMAGING
MRI is becoming increasingly important in myositis
and neuromuscular diseases in general. Its role in
the diagnosis and management of inherited muscle
diseases and inflammatory myopathies, including
IBM, has recently been comprehensively reviewed
[48,49].
Qualitative conventional MRI techniques have
mainly been used to define disease-specific patterns
of muscle involvement. MRI can also be useful to
monitor disease progression and response to treat-
ment, or to direct the muscle biopsy, especially in
inflammatory muscle diseases.
T1-weighted sequences are usually used to
detect chronic muscle disease (fatty infiltration).
The short tau inversion recovery (STIR) sequence
is usually used to detect acute pathology (inflam-
mation) (Fig. 2). Consistently with previous obser-
vations, in a cohort of 32 IBMpatients, Cox et al. [50]
recently reported that muscle inflammation was less
common than fatty infiltration in IBM and that the
number of muscles infiltrated with fat correlated
with weakness and disability. Fatty infiltrationopyright © Lippincott Williams & Wilkins. Unautho
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flexors, anterior muscles of the tights (often with
relative sparing of the rectus femoris) and all the
muscles of the lower leg, particularly the medial
part of the gastrocnemius. There was no disease
control group in this study, which limits its
interpretation. Patchy areas ofmuscle inflammation
or proximal involvement can be suggestive of both
polymyositis and dermatomyositis, while myofas-
cial oedema or a reticular subcutaneous pattern is
more typical of dermatomyositis [51].
Quantitative MRI techniques such as the three-
point Dixon fat-water quantification, T1-relaxome-
try, T2-relaxometry and magnetization transfer
imaging are currently being evaluated in IBM and
other muscle diseases and may prove to be reliable
and sensitive outcome measures for clinical trials
and observational studies [48,49].
Increased Pittsburgh Compound B [a PET bio-
marker that detects amyloid b) uptake levels in the
gastrocnemius muscle have recently been described
in seven IBM patients (compared with six non-IBM
patients) [52]. Larger studies with this PET bio-
marker are needed to confirm these results and to
clarify the potential utility of Pittsburgh Compound
B in clinical practice and in the research setting.TREATMENT
Evidence-based treatment recommendations can-
not be made in IBM and the limited studies
[3,53
&
] so far have shown that the disease is resistant
to immunosuppressive drugs. A recent retrospectiverized reproduction of this article is prohibited.
Volume 25  Number 6  November 2013
FIGURE 2. Transverse T1-weighted (upper slice) and STIR image (bottom slice) of the thighs of patients with inclusion body
myositis. Upper row: note the fatty infiltration (areas of increased signal) predominantly of the anterior muscles of the thigh.
Bottom row: note the areas of high signal in the right thigh (also in the anterior muscles), indicating muscle oedema
(inflammation).
Update in inclusion body myositis Machado et al.study [54] in 16 IBM patients suggested short-term
benefit of intravenous immunoglobulin (IVIg) treat-
ment on muscle strength and dysphagia. However,
this benefit was only temporary and limited to a
small proportion of patients. The role of IVIg in the
treatment of IBM is yet to be clarified in an
adequately powered randomized controlled trial
(RCT).
The effects of exercise in patients with inflam-
matory myopathies, including IBM, have been
recently reviewed [55
&
]. There are promising data
from open-label studies, but larger RCTs are needed
to evaluate the possible effect of exercise in IBM
[55
&
]. A randomized cross-over trial (n¼30) aimed at
investigating the effect of aerobic training in IBM is
currently recruiting patients [56].
Other potential new therapeutic agents are
being investigated in early phase studies. Modulat-
ing the cytoprotective heat shock response (HSR)
represents a therapeutic strategy through which
the detrimental aspects of both inflammation andCopyright © Lippincott Williams & Wilkins. Unau
1040-8711  2013 Wolters Kluwer Health | Lippincott Williams & Wilkdegeneration could be dampened. A placebo-
controlled trial with arimoclomol (16 active drug,
eight placebo), an orally administered pharmaco-
logical agent that can upregulate the HSR by ampli-
fying heat shock protein expression, was recently
reported in abstract format. Arimoclomol was well
tolerated and demonstrated a preliminary signal for
potential therapeutic benefit in patients with IBM,
supporting further research of arimoclomol in this
disease [57].
Antagonists of myostatin could potentially be
used as therapeutic agents in IBM. Myostatin is a
protein that negatively regulates skeletal muscle
growth, and myostatin antagonists have shown
promise for increasing muscle mass and strength
in animal studies. The myostatin pathway is cur-
rently being investigated in two studies. A placebo-
controlled trial (11 active, three placebo) with
BYM338, an intravenously administered mAb that
binds competitively to activin receptor type IIB
with greater affinity than myostatin, was recentlythorized reproduction of this article is prohibited.
ins www.co-rheumatology.com 769
CMyositis and myopathiescompleted and results are awaited [58]. Intramus-
cular follistatin gene transfer (follistatin is a natu-
rally occurring antagonist ofmyostatin) is also being
tested in an open-trial enrolling nine IBM patients
[59].
Etanercept, a tumour necrosis factor (TNF)
antagonist administered subcutaneously, is cur-
rently being tested in a placebo-controlled study
[60] with 30 patients. Results from one open-label
study [61] evaluating 20 patients treated with lith-
ium are also expected; animal studies have shown
that lithium can modulate tau phosphorylation via
suppression of glycogen synthase kinase-3b.CONCLUSION
IBM is still an enigmatic and often misdiagnosed
disease. The pathogenesis of the disease is not fully
understood and pharmacological treatments have
failed to show efficacy. However, recent advances
and the increasing efforts of the scientific com-
munity to disentangle the disease mechanisms
allow us to be optimistic about the future. New
diagnostic criteria have been proposed by the
ENMC, reflecting the knowledge that typical patho-
logical findings may be absent in patients with
clinically typical IBM. The new anti-cN1A antibody
represents an important advance that may help
early diagnosis in clinical practice. The role of
MRI in IBM is expanding, not only as a diagnostic
tool but also as a potential outcome measure in
clinical trials. New therapeutic avenues are being
explored and some of these may progress into effi-
cacy trials. Future research should focus on increas-
ing understanding of the pathophysiological
mechanisms of the disease and on the identification
of reliable and sensitive outcome measures for
clinical trials. International collaboration will be
particularly important to translate research advan-
ces into tangible patient benefits and improved
patient outcomes.Acknowledgements
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